1. Can phytochemical agents manage prostate cancer morbidity and mortality?
A systematic review, published in the British Journal of Urology International (BJUI) evaluated the evidence from randomised trials of phytotherapeutic interventions in the management of prostate cancer recurrence and disease progression. Phytochemicals are compounds that are produced by plants and the researchers of this review assessed 23 articles, with only five meeting the criteria for inclusion. The interventions investigated looked at phytochemical agents including lycopene, soy protein, pomegranate extract, green tea and broccoli sprouts.
The results from the review indicated there is limited evidence that the phytochemicals such as sulphoraphane, lycopene, soy isoflavones, and pomegranate extracts (e.g. POMx, and Pomi-T) can affect PSA dynamics, although the data indicates they are safe and well-tolerated. In conclusion the authors stated no recommendation can be made for the use of these agents in managing prostate cancer morbidity and mortality until high-quality, fully powered, placebo-controlled studies are available.